(Q53300553)

English

Imaging and biomarkers will be used for detection and monitoring progression of early Alzheimer's disease.

scientific article published in April 2009

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19300869

0 references

Imaging and biomarkers will be used for detection and monitoring progression of early Alzheimer's disease. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19300869

1 reference

based on heuristic

inferred from title

author name string

M W Weiner

1

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19300869

publication date

1 April 2009

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19300869

The Journal of Nutrition, Health and Aging

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19300869

13

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19300869

4

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19300869

332

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19300869

Interpreting biomarker data in therapeutic trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/19300869

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

How can we recognize "disease modification" effects?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19300869

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19300869

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biomarkers for Alzheimer's disease trials--biomarkers for what? A discussion paper.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19300869

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

What we have learned from the Xaliproden Sanofi-aventis trials.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19300869

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular imaging markers in clinical trials in Alzheimer s disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19300869

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Knowing the natural course of biomarkers in AD: longitudinal MRI, CSF and PET data

1 reference

https://pubmed.ncbi.nlm.nih.gov/19300869

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES).

1 reference

https://pubmed.ncbi.nlm.nih.gov/19300869

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuro-imaging: structural and functional imaging

1 reference

https://pubmed.ncbi.nlm.nih.gov/19300869

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of biomarkers to select the target population for clinical trials in subjects with mild cognitive impairment

1 reference

https://pubmed.ncbi.nlm.nih.gov/19300869

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interest of the new criteria for drug trials in AD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19300869

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

What we have learned from the Myriad trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/19300869

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biomarkers in clinical trials of Alzheimer disease (AD): what is expected from regulatory agencies?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19300869

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/19300869

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of CSF biomarkers in Alzheimer's disease clinical trials.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19300869

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enrichment of MCI and early Alzheimer's disease treatment trials using neurochemical and imaging candidate biomarkers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19300869

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structural imaging markers for therapeutic trials in Alzheimer's disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19300869

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12603-009-0032-Y

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19300869

release_jjzij2vbtjg2larymntj2qzusu

1 reference

https://api.fatcat.wiki/v0/release/jjzij2vbtjg2larymntj2qzusu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/19300869

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53300553&oldid=2212068034"